Skip to main content
SpringerLink
Log in

Therapie und Prävention

Depotspritze gegen HIV

Long-acting shot against HIV

  • FORTBILDUNG . ÜBERSICHT
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Die Entwicklung von HIV-Medikamenten geht in die nächste Phase. Lang wirksame Depotpräparate führten in klinischen Studien bereits zu ersten Erfolgen. Patienten, die nur alle vier bis acht Wochen ihre Medikamente injizieren mussten, zeigten sich zufrieden.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Langebeek N, Gisolf EH, Reiss P, Vervoort SC, Hafsteinsdóttir TB, Richter C, Sprangers MA, Nieuwkerk PT. Predictors and correlates of adherence to combination antiretroviral therapy (ART) for chronic HIV infection: a meta-analysis. BMC Med 2014; 12:142.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Whitfield T, Torkington A, van Halsema C. Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date. HIV AIDS (Auckl) 2016; 8: 157–164.

    Google Scholar 

  3. Margolis DA, Podzamczer D, Stellbrink HJ, Thomas Lutz T, Jonathan B. Angel JB, Gary Richmond G, et al. Cabotegravir + Rilpivirine as long-acting maintenance therapy: LATTE 2 week 48 results. 21th Int. AIDS Conference 2016, Durban, South Africa, Abstract THAB0206LB.

  4. Jackson A, Else L, Tija J, Seymour N, Stafford M, Back D, Gazzard B, Boffito M. Rilpivirine-LA Formulation: Pharmacokinetics in plasma, genital tract in HIV-females and rectum in males. 19th CROI 2012, Seattle, USA, Abstract 35.

  5. Meyers, K, Rodriguez K, Robert W, Moeller RW, Gratch I, Markowitz M, Halkitis PN. High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy. PLoS One 2014; 9(12): e114700.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Parsons JT, Rendina HJ, Whitfield TH, Grov C. Familiarity with and preferences for oral and long-acting Injectable HIV pre-exposure prophylaxis (PrEP) in a national sample of gay and bisexual men in the U.S. AIDS Behav 2016; 20(7): 1390–9.

    Article  PubMed  Google Scholar 

  7. Andrews CD, Heneine W. Cabotegravir long-acting for HIV-1 prevention. Curr Opin HIV AIDS 2015; 10(4): 258–63.

    Article  CAS  PubMed  Google Scholar 

  8. Andrews CD, Yueh YL, Spreen WR, St Bernard L, Boente-Carrera M, Rodriguez K, et al. A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge. Sci Transl Med 2015; 7(270): 270ra4.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Andrews CD, Spreen WR, Mohri H, Moss L, Ford S, Gettie A, Russell-Lodrigue K, Bohm RP, Cheng-Mayer C, Hong Z, Markowitz M, Ho DD. Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science 2014; 343(6175): 1151–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Andrews, Bernard LS, Poon A, Spreen W, Gettie A, Russell-Lodrigue K, et al. Cabotegravir long-acting injection protects macaques against intravenous challenge. 23rd CROI 2016, Boston, MA,USA, Abstract 105.

  11. Radzio J, Spreen W, Yueh YL, Mitchell J, Jenkins L, García-Lerma JG, Heneine W. The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge. Sci Transl Med 2015; 7(270): 270ra5.

    Article  PubMed  Google Scholar 

  12. Whitfield T, Torkington A, van Halsema C. Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date. HIV AIDS (Auckl) 2016; 8: 157–164.

    Google Scholar 

  13. Kovarova, M., et al., A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges. J Antimicrob Chemother 2016; 71(6): 1586–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Markowitz M, Frank I, Grant RM, Mayer KH, Margolis DA, Hudson KJ, et al. ECLAIR: Phase 2A safety and PK study of cabotegravir LA in HIV Uninfected Men. 23rd CROI 2016, Boston, MA, Abstract 106.

  15. Ford S. ECLAIR Study of Cabotegravir LA Injections: Characterization of Safety and PK During the “PK Tail” Phase. HIV Research for Prevention (HIVR4P) conference 2016, Chicago, USA, Abstract OA12.06LB.

  16. Gunawardana M, Remedios-Chan M, Miller CS, Fanter R, Yang F, Marzinke MA. Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis. Antimicrob Agents Chemother 2015; 59(7): 3913–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Durham PG, Gatto G, Johnson L, Marzinke MA, Swarner S, Rothrock G, et al. In vitro and in vivo evaluation of biodegradable implant containing TAF for HIV PrEP. 24th CROI 2017, Seattle, WA, USA, Abstract 420.

  18. Schlesinger E, Johengen D, Luecke E, Rothrock G, McGowan I, van der Straten A, et al. Thin-film polymer device as a long-acting implant delivering tenofovir alafenamide fumarate for HIV pre-exposure prophylaxis. Pharm Res 2016; 33(7): 1649–56.

    Article  CAS  PubMed  Google Scholar 

  19. Xuan Chua C, Priya J, Hu M, Peter L, Anderson PL, Kimata JT, et al. Transcutaneous refillable nanofluidic implant for constant delivery of HIV PrEP. 24th CROI 2017, Seattle, WA, USA, Abstract 422LB.

  20. Lalezari J, Dhody K., Kowalczyk U, Kazem Kazempour K, Nader Pourhassan N, Maddon PJ. PRO140 single-agent maintenance therapy for HIV-1 infection: A 2-year update. 24th CROI 2017, Seattle, WA, USA, Abstract 437.

  21. Friedman E, Schuermann D, Rudd DJ, Fox-Bosetti S, Zhang S, Robberechts M, Hueser A, Hazuda DJ, Iwamoto M, Grobler J; for the HIV Early Development Teaml. A single monotherapy dose of MK-8591, a novel NRTI, suppresses HIV for 10 days. 23rd CROI 2016, Boston, MA, USA, Abstract 437LB.

  22. Krystal M, Wensel D, Sun Y, Davis J, Li Z, McDonagh T,et al. HIV1 Combinectin GSK3732394 A long-acting inhibitor with multiple modes of action. HIV Drug Therapy 2016, Glasgow, Scottland, Abstract P022.

  23. Tse CW, John O. Discovery of novel potent HIV capsid inhibitor with long-acting potential. 24th CROI 2017, Seattle, WA, USA, Abstract 38.

Download references

Author information

Authors and Affiliations

  1. MVZ Karlsplatz, Karlsplatz 8, D-80335, München, Deutschland

    Eva Wolf MPH &  Sebastian Noe

Authors
  1. Eva Wolf MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sebastian Noe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eva Wolf MPH.

Additional information

This article is part of a supplement not sponsored by the industry.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wolf, E., Noe, S. Depotspritze gegen HIV. MMW - Fortschritte der Medizin 159 (Suppl 2), 36–38 (2017). https://doi.org/10.1007/s15006-017-9734-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-017-9734-y

Keywords

Search

Navigation